Search

A 46-year-old man with glioblastoma (GBM) exhibited lack of efficacy during treatment with temozolomide and irinotecan. He developed a flu-like syndrome during off-label treatment with interferon-gamma-1a and thymalfasin for GBM. Despite experiencing flu-like symptoms, he achieved complete tumour regression with cytokine genetic therapy (CGT) consisting of interferon-gamma-1a and thymalfasin. The patient's overall condition improved, and he continued CGT with no signs of tumour growth. [Extracted from the article]

A 74-year-old man developed an urticarial rash while being treated with piperacillin/tazobactam for pleural effusion. The man had a medical history of various conditions, including an ischaemic stroke and acute pulmonary edema. After developing the rash, his medication was changed and he was eventually diagnosed with Cutibacterium acnes and acalculous cholecystitis. With the use of antibiotics, his condition improved and he was discharged from the hospital. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 29-year-old man developed acute acalculous cholecystitis following vaccination against COVID -19 with Ad26.COV2-S. Additionally, he exhibited no therapeutic response during treatment with diclofenac, paracetamol and Ringer's-lactate for acute acalculous cholecystitis [ I not all routes and dosages stated i ]. Based on symptoms and investigations, he was diagnosed with acute acalculous cholecystitis secondary to Ad26.COV2-S. The man was then treated with an IV infusion of paracetamol 1 g/day, IV diclofenac ampule 75 mg/day and IV Ringer's-lactate 1 L/day. Despite receiving diclofenac, paracetamol and Ringer's-lactate treatment, he did not show therapeutic response. [Extracted from the article]

DRESS syndrome with cholecystitis in a child: A case report and literature review. Based on the presentation, it was noted that she developed DRESS syndrome and acute acalculous cholecystitis secondary to sulfasalazine. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 12-year-old girl developed DRESS syndrome and acute acalculous cholecystitis during treatment with sulfasalazine for Crohn's disease. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 52-year-old woman developed injection site pain, severe arthralgia and acute acalculous cholecystitis following administration of tozinameran as prophylactic vaccination. At around 7:00PM, she developed whole-body muscle cramps, severe shivering and massive swelling of the injection site, along with nausea and vomiting for five hours. [Extracted from the article]

Acute Acalculous Cholecystitis in a Multiple Sclerosis Patient Treated with Natalizumab. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 37-year-old woman developed parvovirus B19 (B19V) infection and acute acalculous cholecystitis (AAC) during treatment with natalizumab for relapsing-remitting multiple sclerosis (RR-MS) [ I time to reactions onsets not stated i ]. Her serologic tests including IgM and IgG antibodies tests were positive for B19V infection, which was considered as secondary to the immunosuppressive effect of the natalizumab therapy. [Extracted from the article]

Ultrasound showed gallbladder wall thickening, which was consistent with acalculous cholecystitis. He developed acute respiratory and renal failure and thus required veno-venous extracorporeal membrane oxygenation, renal replacement therapy, vasopressor support and intubation. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 35-year-old man developed acalculous cholecystitis secondary to I Candida albicans i infection during off-label therapy with hydrocortisone and tocilizumab for COVID-19 pneumonia [ I routes, dosages and durations of treatment to reactions onset not stated i ]. [Extracted from the article]

Patient 1 (82-year-old woman): The woman started receiving off label treatment with lopinavir/ritonavir 400mg/100mg twice daily for COVID-19. She had been on mometasone therapy, which was changed to beclomethasone on day 4 of lopinavir/ritonavir therapy. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose * Drug interaction In a case series involving 12 patients, 9 patients (5 men and 4 women admitted to the hospital in Canada) aged 28-84 years were described, who developed diarrhoea, anorexia, nausea, vomiting, hyponatraemia, elevation in bilirubin level, hyperkalaemia, adrenal insufficiency, elevation in ALT, hypophosphataemia, elevation in triglycerides level, acalculous cholecystitis or hypertriglyceridemia following off label treatment with lopinavir/ritonavir for COVID-19. [Extracted from the article]

The article presents the case studies of a 26-year-old female and 29-year-old male suffering from allergic inflammatory syndrome and eosinophilc acalculous cholecystitis after administration with alemtuzumab.

The article presents a study which reveals an association between acute acalculous cholecystitis (AAC) and alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS), resulting to the modification of the product label for alemtuzumab for RRMS to include AAC.

Several case studies are presented of patients, who have developed acute acalculous cholecystitis (AAC) during treatment with alemtuzumab for highly active relapsing-remitting multiple sclerosis (RRMS).